secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2023-08-01T23:59:59+00:00
Accession:  0001517022-23-000023
Event type: leadership
Sentiment:  neutral
Materiality: 0.30
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Akebia extends COO Dahan and CLO Hadas separation dates to 2024
---------------------------------------------------------------

- COO Michel Dahan termination extended to March 22, 2024 (could extend to Sept 22, 2024 under certain events).
- Chief Legal Officer Nicole Hadas termination extended to Oct 6, 2023 (could extend to March 22, 2024).
- Both changes are amendments to retention/separation agreements from Nov 2022 and May 2023.
- Extensions are part of the workforce reduction announced May 9, 2022.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702223000023/0001517022-23-000023-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702223000023/akba-20230726.htm
  HTML page:      https://secwatch.observer/filing/0001517022-23-000023

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer